SOFTSERVE
19.10.2021 13:07:55 CEST | Business Wire | Press release
SoftServe , a leading digital authority and consulting company, has appointed Alfredo Rubina as Vice President Financial Services Domain Solutions and Consulting, effective immediately. Rubina has 25 years of international experience in enterprise technology and software sales, business development, and general management in the financial services industry. As VP Financial Services, he will be responsible for defining and building SoftServe’s financial services domain growth and go-to-market strategy in EMEA, including driving vertical roadmap and the development of offerings/accelerators, building sales channels, and developing relationships with client organizations and partner companies. Rubina will report to Volodymyr Semenyshyn, SoftServe’s Executive Vice President EMEA and Financial Services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211019005014/en/
"Alfredo brings to SoftServe impressive experience working internationally with top-tier financial and corporate firms at the highest levels," said Semenyshyn. "I am excited to have him oversee our financial services domain and build and lead teams that deliver solutions and services that help our clients reach their goals."
“SoftServe has a history of successfully delivering client value through developing win-win relationships and finding innovative solutions in a fast-changing business environment,” said Rubina. “As VP Financial Services, I will focus on helping financial institutions identify trends, master challenges, unlock opportunities and enable transformation through new digital technologies. It is my goal to help customers grow their business, increase efficiency and reduce costs, as well as to fuel SoftServe’s continuous and rapid rate of growth in EMEA.”
Prior to joining SoftServe, Rubina managed strategy and go-to-market as Head of IHS Markit’s Digital franchise in EMEA and Latin America, with full P&L responsibility for the business and its successful growth with new clients, customer segments, and markets in different countries.
Before IHS Markit, Rubina was with Interactive Data Managed Solutions AG for more than 15 years, establishing and expanding the digital business into a leading global provider of bespoke solutions for the financial industry.
Rubina was also previously with investment banking sector and the German retail banking and savings bank organizations, holding a variety of account management, sales, and business development roles.
Rubina studied Business Informatics and Business Administration at the University of Mannheim after a Banking Professional apprenticeship at Sparkasse Mannheim.
A cosmopolitan German of Peruvian origin, Rubina loves sports and is an avid fan of music. Together with his wife, he raises two daughters and cares for a very special and rare Bergamasco Shepherd. A vehement supporter of social responsibility, environmental protection, and animal welfare, Rubina is an active volunteer at The Tafel, the largest food donation organization in Germany, and is engaged with The German Animal Welfare Federation. He also compensates his CO2 footprint with Compensators, a non-profit organization that buys emission allowances from the European Emissions Trading Scheme and decommissions them permanently.
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation, from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website , blog , LinkedIn , Facebook , and Twitter pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005014/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom